1. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
- Author
-
Sumiyoshi, Remi, Koga, Tomohiro, Fukui, Shoichi, Furukawa, Kaori, Momoki, Mamiko, Ichinose, Kunihiro, Yano, Shingo, and Kawakami, Atsushi
- Subjects
- *
SOMATOMEDIN , *CASTLEMAN'S disease , *BLOOD proteins , *CELLULAR signal transduction , *RNA sequencing , *SYSTEMIC lupus erythematosus , *MYELOFIBROSIS - Abstract
To determine the molecular differences between iMCD-thrombocytopenia, anasarca, fevers, reticulin myelofibrosis, organomegaly (TAFRO), and iMCD-not otherwise specified (NOS). CD4-positive T cells were isolated from two iMCD-TAFRO and two iMCD-NOS patients for RNA sequencing comparison. Serum proteins of two iMCD-TAFRO and four iMCD-NOS patients were comprehensively analyzed to identify pathogenesis-associated proteins. IGFBP-1 protein, extracted from serum analysis, was compared to healthy controls, iMCD, systemic lupus erythematosus, and rheumatoid arthritis patients. RNA sequencing of CD4-positive T cells revealed enhanced mTOR-related signaling in iMCD-TAFRO compared to iMCD-NOS. Comprehensive serum analysis found IGFBP-1 linked to iMCD pathogenesis, significantly higher in iMCD-TAFRO. This protein may be elevated in patients with iMCD caused by an enhanced mTOR pathway. The mTOR pathway is suggested to be activated in iMCD-TAFRO compared to iMCD-NOS, which may elevate the protein IGFBP-1. This protein may be a biomarker to distinguish iMCD-TAFRO from iMCD-NOS. • The mTOR pathway is suggested to be activated in iMCD-TAFRO compared to iMCD-NOS. • Elevated serum IGFBP-1 may be associated with activation of the mTOR pathway. • Serum IGFBP-1 may be a biomarker to distinguish between iMCD-TAFRO and iMCD-NOS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF